Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

DelMar Pharma to Raise $8 Million in Private Placement

publication date: Jun 19, 2015
DelMar Pharma, a Vancouver-Menlo Park drug developer with significant ties to China, announced plans to raise up to $8 million in a secondary offering. Two weeks ago, the company reported positive data from an early-stage trial of VAL-083 in patients with gliobastoma multiforme. DelMar sources VAL-083 from Guangxi Wuzhou Pharma in China, where it is approved to treat leukemia and lung cancer. DelMar owns China rights to the drug for the glioblastoma multiforme indication. More details....

Stock Symbol: (OTC: DMPI)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital